Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of -3.46% and Operating profit at -163.01% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 5.85% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -3.46% and Operating profit at -163.01% over the last 5 years
3
Positive results in Mar 26
4
With ROE of 0.11%, it has a expensive valuation with a 2.36 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 732 Million (Small Cap)
2,194.00
NA
0.80%
-0.32
0.32%
0.40
Revenue and Profits:
Net Sales:
141 Million
(Quarterly Results - Mar 2026)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.16%
0%
-9.16%
6 Months
10.49%
0%
10.49%
1 Year
41.7%
0%
41.7%
2 Years
34.6%
0%
34.6%
3 Years
-17.08%
0%
-17.08%
4 Years
-54.87%
0%
-54.87%
5 Years
0%
0%
0.0%
Caina Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.46%
EBIT Growth (5y)
-163.01%
EBIT to Interest (avg)
89.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.21
Tax Ratio
4.45%
Dividend Payout Ratio
86.96%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.25%
ROE (avg)
5.85%
Valuation key factors
Factor
Value
P/E Ratio
2194
Industry P/E
Price to Book Value
2.36
EV to EBIT
-166.21
EV to EBITDA
191.35
EV to Capital Employed
3.49
EV to Sales
9.98
PEG Ratio
NA
Dividend Yield
0.14%
ROCE (Latest)
-2.10%
ROE (Latest)
0.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
141.30
72.70
94.36%
Operating Profit (PBDIT) excl Other Income
11.80
16.40
-28.05%
Interest
1.00
0.00
Exceptional Items
1.60
1.90
-15.79%
Consolidate Net Profit
11.30
7.30
54.79%
Operating Profit Margin (Excl OI)
83.10%
38.90%
4.42%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 94.36% vs -34.27% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 54.79% vs -70.80% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
354.90
386.80
-8.25%
Operating Profit (PBDIT) excl Other Income
52.50
64.30
-18.35%
Interest
0.60
0.40
50.00%
Exceptional Items
-10.50
2.50
-520.00%
Consolidate Net Profit
2.60
52.30
-95.03%
Operating Profit Margin (Excl OI)
-10.20%
60.90%
-7.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -8.25% vs -5.64% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -95.03% vs -53.55% in Dec 2024
About Caina Technology Co., Ltd. 
Caina Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






